arrow
F

Frederick W. Thielen

Erasmus University Rotterdam
H指数:10
被引数:1,195

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost‐Effectiveness of Early Dose Reduction or Discontinuation Versus Antipsychotic Maintenance After First‐Episode Psychosis: Results From the HAMLETT Study

首发精神分裂症后早期减量或停药与抗精神病药维持治疗的成本效益比较:<scp>HAMLETT</scp>研究的结果

2026-11-040
OAAI
The European CAR-T map—Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies

欧洲CAR-T地图——当前状况和未来方向:改善血液恶性肿瘤CAR T细胞疗法的可及性

2026-03-050
OAAI
Bridging Affordability and Sustainability of Health Innovations via Novel Pricing, Cost-effectiveness, and Reimbursement Models to Improve Patient Access: The ASCERTAIN Project
2026-01-100
PRE
Impact of advanced therapies for inflammatory bowel disease on disease activity, health-related quality of life, fatigue and psychological symptoms - real-world evidence from a prospective pilot cohort study at a tertiary care center

炎症性肠病先进疗法对疾病活动度、健康相关生活质量、疲劳和心理症状的影响——来自三级保健中心前瞻性试点队列研究的真实世界证据

2026-01-010
PRE
Research priorities on physical-mental comorbidity in children and adolescents: an international consensus

儿童和青少年身心共患疾病的研究重点:一项国际共识

2025-10-090
OAAI
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

欧洲接受CAR T细胞疗法治疗的血液恶性肿瘤患者的患者报告结局

2025-09-260
OAAI
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe

呼吁保存CAT在推进欧洲ATMPs方面的专业知识和贡献

2025-09-230
OAAI
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review

潜在创新性健康技术的价格决定因素与定价政策:一项范围综述

2025-09-010
OAAI
Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial
2025-03-211
OAAI